By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.

Key Statistics

Ownership: Public

Web Site: Nektar Therapeutics
Employees: 429
Symbol: NKTR

Company News
ASCO2016: Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At ASCO 2016 Annual Meeting Demonstrate That Single-Agent NKTR-214 Produces A Large Increase In Tumor-Infiltrating Lymphocytes To Provide Durable Anti-Tumor Activity 6/7/2016 9:22:49 AM
Bay Area's Nektar Therapeutics (NKTR) Names a New CFO and COO 6/3/2016 5:54:59 AM
Nektar Therapeutics (NKTR), DAIICHI SANKYO EUROPE GmbH Strike $80 Million+ ONZEALD Pact 6/1/2016 6:41:03 AM
Nektar Therapeutics (NKTR) Reports Financial Results For The First Quarter Of 2016 5/4/2016 7:01:41 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The First Quarter 2016 On Tuesday, May 3, 2016, After Close Of U.S.-Based Financial Markets 4/28/2016 7:04:38 AM
Nektar Therapeutics (NKTR) Release: Preclinical Data Presented At AACR Demonstrate That Combining NKTR-214 With Checkpoint Blockade Is Superior To Dual Checkpoint Inhibition In Increasing Clonality Of The T Cell Receptor (TCR) Repertoire And T Cell Tumor Infiltration 4/18/2016 8:15:09 AM
Nektar Therapeutics (NKTR) To Present At Cowen and Company's 36th Annual Health Care Conference In Boston, MA 3/4/2016 9:52:14 AM
Nektar Therapeutics (NKTR) Reports Fourth Quarter And Year-End 2015 Financial Results 3/2/2016 7:28:30 AM
Nektar Therapeutics (NKTR) To Announce Financial Results For The Fourth Quarter And Year-Ended 2015 On Tuesday, March 1, 2016, After Close Of U.S.-Based Financial Markets 2/26/2016 6:34:50 AM
Nektar Therapeutics (NKTR) Publishes Pre-Clinical Results For NKTR-214, An Investigational CD122-Biased Immune-Stimulatory Cytokine For The Treatment Of Cancer In Clinical Cancer Research 2/1/2016 7:26:01 AM